Australian entrepreneurs unveil AI-designed pet mRNA cancer vaccine process, involving 300GB of genetic data and multi-model collaboration.

Gate News reports that on March 27, Paul Conyngham, the founder of an Australian AI consulting company, disclosed on the X platform the complete technical process of designing a personalized mRNA cancer vaccine for a pet dog using several AI chatbots. The dog was diagnosed with malignant mast cell cancer in May 2024, and approximately 300GB of data was obtained through whole-genome and RNA sequencing. With the collaboration of ChatGPT, Gemini, and Grok, target selection, protein structure modeling, and vaccine sequence design were completed, ultimately identifying a c-KIT gene mutation and selecting seven new antigen targets. The vaccine was prepared by a related research team at the University of New South Wales and administered at the University of Queensland’s veterinary school. The overall treatment plan includes the combined use of the mRNA vaccine, tyrosine kinase inhibitors, and PD-1 inhibitors, with the administration schedule planned with AI assistance. Treatment began in December 2025, and within three months, some tumors showed shrinkage, but there remain unresponsive lesions that require surgical intervention. Experts note that this case represents an individual practice and does not yet constitute a universal medical conclusion.